Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets
Identifieur interne : 001161 ( Istex/Corpus ); précédent : 001160; suivant : 001162Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets
Auteurs : Kayhan A. Tayarani-Binazir ; Michael J. Jackson ; Sarah Rose ; C. Warren Olanow ; Peter JennerSource :
- Movement Disorders [ 0885-3185 ] ; 2010-02-15.
English descriptors
- KwdEn :
Abstract
Reduced expression of dyskinesia is observed in levodopa‐primed MPTP‐treated common marmosets when dopamine agonists are used to replace levodopa. We now investigate whether a combination of the D‐2/D‐3 agonist pramipexole and levodopa also reduces dyskinesia intensity while maintaining the reversal of motor disability. Drug naïve, non‐dyskinetic MPTP‐treated common marmosets were treated daily for up to 62 days with levodopa (12.5 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) or pramipexole (0.04–0.3 mg/kg BID) producing equivalent reversal of motor disability and increases in locomotor activity. Levodopa alone resulted in marked dyskinesia induction but little or no dyskinesia resulted from the administration of pramipexole. From day 36, some animals were treated with a combination of levodopa (3.125–6.25 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) and pramipexole (0.1–0.2 mg/kg p.o. SID). This improved motor disability to a greater extent than occurred with levodopa alone. Importantly, while dyskinesia was greater than that produced by pramipexole alone, the combination resulted in less intense dyskinesia than produced by levodopa alone. These results suggest that pramipexole could be administered with a reduced dose of levodopa to minimize dyskinesia in Parkinson's disease while maintaining therapeutic efficacy. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.22960
Links to Exploration step
ISTEX:F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets</title><author><name sortKey="Tayarani Inazir, Kayhan A" sort="Tayarani Inazir, Kayhan A" uniqKey="Tayarani Inazir K" first="Kayhan A." last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name><affiliation><mods:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name><affiliation><mods:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name><affiliation><mods:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><affiliation><mods:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22960</idno><idno type="url">https://api.istex.fr/document/F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001161</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets</title><author><name sortKey="Tayarani Inazir, Kayhan A" sort="Tayarani Inazir, Kayhan A" uniqKey="Tayarani Inazir K" first="Kayhan A." last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name><affiliation><mods:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name><affiliation><mods:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name><affiliation><mods:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><affiliation><mods:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-02-15">2010-02-15</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="377">377</biblScope><biblScope unit="page" to="384">384</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83</idno><idno type="DOI">10.1002/mds.22960</idno><idno type="ArticleID">MDS22960</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>L‐dopa</term><term>MPTP</term><term>Parkinson's disease</term><term>dyskinesia</term><term>motor disability</term><term>pramipexole</term><term>primate</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Reduced expression of dyskinesia is observed in levodopa‐primed MPTP‐treated common marmosets when dopamine agonists are used to replace levodopa. We now investigate whether a combination of the D‐2/D‐3 agonist pramipexole and levodopa also reduces dyskinesia intensity while maintaining the reversal of motor disability. Drug naïve, non‐dyskinetic MPTP‐treated common marmosets were treated daily for up to 62 days with levodopa (12.5 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) or pramipexole (0.04–0.3 mg/kg BID) producing equivalent reversal of motor disability and increases in locomotor activity. Levodopa alone resulted in marked dyskinesia induction but little or no dyskinesia resulted from the administration of pramipexole. From day 36, some animals were treated with a combination of levodopa (3.125–6.25 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) and pramipexole (0.1–0.2 mg/kg p.o. SID). This improved motor disability to a greater extent than occurred with levodopa alone. Importantly, while dyskinesia was greater than that produced by pramipexole alone, the combination resulted in less intense dyskinesia than produced by levodopa alone. These results suggest that pramipexole could be administered with a reduced dose of levodopa to minimize dyskinesia in Parkinson's disease while maintaining therapeutic efficacy. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Kayhan A. Tayarani‐Binazir BSc</name><affiliations><json:string>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Michael J. Jackson BSc</name><affiliations><json:string>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Sarah Rose PhD</name><affiliations><json:string>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</json:string></affiliations></json:item><json:item><name>C. Warren Olanow MD</name><affiliations><json:string>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Peter Jenner DSc</name><affiliations><json:string>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>pramipexole</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>L‐dopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>motor disability</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dyskinesia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MPTP</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>primate</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Reduced expression of dyskinesia is observed in levodopa‐primed MPTP‐treated common marmosets when dopamine agonists are used to replace levodopa. We now investigate whether a combination of the D‐2/D‐3 agonist pramipexole and levodopa also reduces dyskinesia intensity while maintaining the reversal of motor disability. Drug naïve, non‐dyskinetic MPTP‐treated common marmosets were treated daily for up to 62 days with levodopa (12.5 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) or pramipexole (0.04–0.3 mg/kg BID) producing equivalent reversal of motor disability and increases in locomotor activity. Levodopa alone resulted in marked dyskinesia induction but little or no dyskinesia resulted from the administration of pramipexole. From day 36, some animals were treated with a combination of levodopa (3.125–6.25 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) and pramipexole (0.1–0.2 mg/kg p.o. SID). This improved motor disability to a greater extent than occurred with levodopa alone. Importantly, while dyskinesia was greater than that produced by pramipexole alone, the combination resulted in less intense dyskinesia than produced by levodopa alone. These results suggest that pramipexole could be administered with a reduced dose of levodopa to minimize dyskinesia in Parkinson's disease while maintaining therapeutic efficacy. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>6.502</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1364</abstractCharCount><pdfWordCount>4198</pdfWordCount><pdfCharCount>26980</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>192</abstractWordCount></qualityIndicators><title>Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets</title><genre><json:string>Serial article</json:string></genre><host><volume>25</volume><pages><total>8</total><last>384</last><first>377</first></pages><issn><json:string>0885-3185</json:string></issn><issue>3</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.22960</json:string></doi><id>F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: None reported.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets</title><author><persName><forename type="first">Kayhan A.</forename><surname>Tayarani‐Binazir</surname><roleName type="degree">BSc</roleName></persName><affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</affiliation></author><author><persName><forename type="first">Michael J.</forename><surname>Jackson</surname><roleName type="degree">BSc</roleName></persName><affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</affiliation></author><author><persName><forename type="first">Sarah</forename><surname>Rose</surname><roleName type="degree">PhD</roleName></persName><affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</affiliation></author><author><persName><forename type="first">C. Warren</forename><surname>Olanow</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</affiliation></author><author><persName><forename type="first">Peter</forename><surname>Jenner</surname><roleName type="degree">DSc</roleName></persName><note type="correspondence"><p>Correspondence: School of Biomedical Health and Sciences, King's College London, London SE1 1UL, United Kingdom===</p></note><affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-02-15"></date><biblScope unit="vol">25</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="377">377</biblScope><biblScope unit="page" to="384">384</biblScope></imprint></monogr><idno type="istex">F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83</idno><idno type="DOI">10.1002/mds.22960</idno><idno type="ArticleID">MDS22960</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Reduced expression of dyskinesia is observed in levodopa‐primed MPTP‐treated common marmosets when dopamine agonists are used to replace levodopa. We now investigate whether a combination of the D‐2/D‐3 agonist pramipexole and levodopa also reduces dyskinesia intensity while maintaining the reversal of motor disability. Drug naïve, non‐dyskinetic MPTP‐treated common marmosets were treated daily for up to 62 days with levodopa (12.5 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) or pramipexole (0.04–0.3 mg/kg BID) producing equivalent reversal of motor disability and increases in locomotor activity. Levodopa alone resulted in marked dyskinesia induction but little or no dyskinesia resulted from the administration of pramipexole. From day 36, some animals were treated with a combination of levodopa (3.125–6.25 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) and pramipexole (0.1–0.2 mg/kg p.o. SID). This improved motor disability to a greater extent than occurred with levodopa alone. Importantly, while dyskinesia was greater than that produced by pramipexole alone, the combination resulted in less intense dyskinesia than produced by levodopa alone. These results suggest that pramipexole could be administered with a reduced dose of levodopa to minimize dyskinesia in Parkinson's disease while maintaining therapeutic efficacy. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>pramipexole</term></item><item><term>L‐dopa</term></item><item><term>motor disability</term></item><item><term>dyskinesia</term></item><item><term>MPTP</term></item><item><term>primate</term></item><item><term>Parkinson's disease</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-10-06">Received</change><change when="2009-11-15">Registration</change><change when="2010-02-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/mds.v25:3</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="2010-02-15">15 February 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="180" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22960</doi><idGroup><id type="unit" value="MDS22960"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2009-10-06"></event><event type="manuscriptRevised" date="2009-11-12"></event><event type="manuscriptAccepted" date="2009-11-15"></event><event type="firstOnline" date="2010-01-27"></event><event type="publishedOnlineFinalForm" date="2010-02-24"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2010-01-27"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.3.2 mode:FullText" date="2014-07-01"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.3.2 mode:FullText" date="2014-07-01"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">377</numbering><numbering type="pageLast">384</numbering></numberingGroup><correspondenceTo>School of Biomedical Health and Sciences, King's College London, London SE1 1UL, United Kingdom===</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22960.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="41"></count><count type="wordTotal" number="4423"></count></countGroup><titleGroup><title type="main" xml:lang="en">Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets<link href="#fn1"></link></title><title type="short" xml:lang="en">Pramipexole Combined with <sc>L</sc>‐Dopa</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Kayhan A.</givenNames><familyName>Tayarani‐Binazir</familyName><degrees>BSc</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Michael J.</givenNames><familyName>Jackson</familyName><degrees>BSc</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Sarah</givenNames><familyName>Rose</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>C. Warren</givenNames><familyName>Olanow</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Peter</givenNames><familyName>Jenner</familyName><degrees>DSc</degrees></personName><contactDetails><email>peter.jenner@kcl.ac.uk</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">pramipexole</keyword><keyword xml:id="kwd2"><sc>L</sc>‐dopa</keyword><keyword xml:id="kwd3">motor disability</keyword><keyword xml:id="kwd4">dyskinesia</keyword><keyword xml:id="kwd5">MPTP</keyword><keyword xml:id="kwd6">primate</keyword><keyword xml:id="kwd7">Parkinson's disease</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Reduced expression of dyskinesia is observed in levodopa‐primed MPTP‐treated common marmosets when dopamine agonists are used to replace levodopa. We now investigate whether a combination of the D‐2/D‐3 agonist pramipexole and levodopa also reduces dyskinesia intensity while maintaining the reversal of motor disability. Drug naïve, non‐dyskinetic MPTP‐treated common marmosets were treated daily for up to 62 days with levodopa (12.5 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) or pramipexole (0.04–0.3 mg/kg BID) producing equivalent reversal of motor disability and increases in locomotor activity. Levodopa alone resulted in marked dyskinesia induction but little or no dyskinesia resulted from the administration of pramipexole. From day 36, some animals were treated with a combination of levodopa (3.125–6.25 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) and pramipexole (0.1–0.2 mg/kg p.o. SID). This improved motor disability to a greater extent than occurred with levodopa alone. Importantly, while dyskinesia was greater than that produced by pramipexole alone, the combination resulted in less intense dyskinesia than produced by levodopa alone. These results suggest that pramipexole could be administered with a reduced dose of levodopa to minimize dyskinesia in Parkinson's disease while maintaining therapeutic efficacy. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: None reported.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Pramipexole Combined with L‐Dopa</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets</title></titleInfo><name type="personal"><namePart type="given">Kayhan A.</namePart><namePart type="family">Tayarani‐Binazir</namePart><namePart type="termsOfAddress">BSc</namePart><affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael J.</namePart><namePart type="family">Jackson</namePart><namePart type="termsOfAddress">BSc</namePart><affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sarah</namePart><namePart type="family">Rose</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C. Warren</namePart><namePart type="family">Olanow</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Peter</namePart><namePart type="family">Jenner</namePart><namePart type="termsOfAddress">DSc</namePart><affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom</affiliation><description>Correspondence: School of Biomedical Health and Sciences, King's College London, London SE1 1UL, United Kingdom===</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-02-15</dateIssued><dateCaptured encoding="w3cdtf">2009-10-06</dateCaptured><dateValid encoding="w3cdtf">2009-11-15</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="references">41</extent><extent unit="words">4423</extent></physicalDescription><abstract lang="en">Reduced expression of dyskinesia is observed in levodopa‐primed MPTP‐treated common marmosets when dopamine agonists are used to replace levodopa. We now investigate whether a combination of the D‐2/D‐3 agonist pramipexole and levodopa also reduces dyskinesia intensity while maintaining the reversal of motor disability. Drug naïve, non‐dyskinetic MPTP‐treated common marmosets were treated daily for up to 62 days with levodopa (12.5 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) or pramipexole (0.04–0.3 mg/kg BID) producing equivalent reversal of motor disability and increases in locomotor activity. Levodopa alone resulted in marked dyskinesia induction but little or no dyskinesia resulted from the administration of pramipexole. From day 36, some animals were treated with a combination of levodopa (3.125–6.25 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) and pramipexole (0.1–0.2 mg/kg p.o. SID). This improved motor disability to a greater extent than occurred with levodopa alone. Importantly, while dyskinesia was greater than that produced by pramipexole alone, the combination resulted in less intense dyskinesia than produced by levodopa alone. These results suggest that pramipexole could be administered with a reduced dose of levodopa to minimize dyskinesia in Parkinson's disease while maintaining therapeutic efficacy. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: None reported.</note><subject lang="en"><genre>Keywords</genre><topic>pramipexole</topic><topic>L‐dopa</topic><topic>motor disability</topic><topic>dyskinesia</topic><topic>MPTP</topic><topic>primate</topic><topic>Parkinson's disease</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>377</start><end>384</end><total>8</total></extent></part></relatedItem><identifier type="istex">F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83</identifier><identifier type="DOI">10.1002/mds.22960</identifier><identifier type="ArticleID">MDS22960</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001161 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001161 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83
|texte= Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets
}}
| This area was generated with Dilib version V0.6.23. |  |